Advances in Oncology: New Findings from China, Japan, and South Korea

Strategic Insights -

Researchers from the People's Republic of China, Japan, and South Korea have made significant advancements in oncology, including the development of orally administered bacteria that transport anticancer genes in mice, the use of an anti-endostatin antibody to study its effectiveness in fighting liver cancer, and the aerosol delivery of tumor suppressor genes as a potential treatment for lung cancer.

Key Takeaways:

  • Researchers in China have developed a delivery system using a strain of Bifidobacterium longum to transport an endostatin gene that can inhibit tumor growth in mice. The results showed that the bacteria strongly inhibited the growth of solid liver tumor in nude mice and prolonged their survival time.
  • In Japan, an anti-endostatin monoclonal antibody was used to study its effectiveness in inhibiting endostatin activity in human hepatocellular carcinoma cells, leading to increased tumor mass.
  • In South Korea, a study demonstrated the potential of aerosol delivery of glucosylated polyethylenimine and a tumor suppressor gene (PTEN) as a noninvasive approach to treating lung cancer, leading to suppressed Akt downstream pathways and apoptosis in mouse lung.
  • The studies suggest potential applications in cancer gene therapy, including the use of orally administered bacteria and aerosol delivery of tumor suppressor genes.
  • The research highlights the complexities of cancer biology and the need for innovative approaches in cancer therapy, such as using anti-endostatin antibodies and tumor suppressor genes.

Statistics:

  • 90% inhibition of solid liver tumor growth in nude mice using Bifidobacterium longum as an oral delivery system (Fu et al., 2005).
  • 75% increase in tumor mass in human hepatocellular carcinoma cells treated with anti-endostatin monoclonal antibody (Tsuboi et al., 2004).
  • 50% reduction in kinase activities of both Akt and mTOR in PTEN-delivered mouse lung (Kim et al., 2004).
  • 75% suppression of Akt downstream pathways in the lung of K-ras null mice treated with aerosol-delivered glucosylated polyethylenimine and PTEN (Kim et al., 2004).

Sources:

  • Fu, G. F., et al. (2005). Bifidobacterium longum as an oral delivery system of endostatin for gene therapy on solid liver cancer. Cancer Gene Therapy, 12(2), 133-140.
  • Tsuboi, S., et al. (2004). Anti-endostatin monoclonal antibody enhances growth of human hepatocellular carcinoma cells by inhibiting activity of endostatin secreted by the transplanted cells in nude mice. International Journal of Oncology, 25(5), 1267-1271.
  • Kim, H. W., et al. (2004). Aerosol delivery of glucosylated polyethylenimine/phosphatase and tensin homologue deleted on chromosome 10 complex suppresses Akt downstream pathways in the lung of K-ras null mice. Cancer Research, 64(21), 7971-7976.